OTX-TP is an intracanalicular prostaglandin analog (PGA) insert currently undergoing Phase 3 clinical evaluation as a treatment targeting mild to moderate glaucoma and ocular hypertension.
OTX -TP Intracanalicular Insert
Relative Insert Size
OTX-TP is a drug product candidate that is intended for insertion into the canaliculus and to deliver travoprost to the ocular surface for up to 90 days without preservatives. The goal of OTX-TP is to deliver a continuous steady release of travoprost throughout the treatment period. Ocular Therapeutix is currently enrolling patients in a phase 3 trial with OTX-TP for the treatment of elevated intraocular pressure in patients targeting mild to moderate open-angle glaucoma or ocular hypertension.
Caution: NEW DRUG – OTX-TP is currently undergoing clinical evaluation in the United States and is limited by United States law to investigational use only. This product has not been approved by the FDA as safe or effective.
“OTX-TP may provide an opportunity to reduce the issue of patient non-compliance that currently affects nearly 50% of glaucoma patients.”
-Antony Mattessich, President and CEO